Chartwell Investment Partners LLC Buys 389 Shares of Loxo Oncology Inc (LOXO)

Share on StockTwits

Chartwell Investment Partners LLC lifted its stake in Loxo Oncology Inc (NASDAQ:LOXO) by 3.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,585 shares of the biopharmaceutical company’s stock after acquiring an additional 389 shares during the period. Chartwell Investment Partners LLC’s holdings in Loxo Oncology were worth $1,763,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in LOXO. State Board of Administration of Florida Retirement System grew its stake in Loxo Oncology by 7.8% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 13,535 shares of the biopharmaceutical company’s stock valued at $1,896,000 after purchasing an additional 976 shares during the last quarter. SG Americas Securities LLC grew its stake in Loxo Oncology by 471.2% during the 4th quarter. SG Americas Securities LLC now owns 7,220 shares of the biopharmaceutical company’s stock valued at $1,011,000 after purchasing an additional 5,956 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its stake in Loxo Oncology by 27.4% during the 4th quarter. Emerald Mutual Fund Advisers Trust now owns 139,619 shares of the biopharmaceutical company’s stock valued at $19,556,000 after purchasing an additional 30,030 shares during the last quarter. Rhumbline Advisers grew its stake in Loxo Oncology by 55.8% during the 4th quarter. Rhumbline Advisers now owns 37,751 shares of the biopharmaceutical company’s stock valued at $5,288,000 after purchasing an additional 13,524 shares during the last quarter. Finally, Advisors Asset Management Inc. grew its stake in Loxo Oncology by 102.0% during the 4th quarter. Advisors Asset Management Inc. now owns 3,793 shares of the biopharmaceutical company’s stock valued at $531,000 after purchasing an additional 1,915 shares during the last quarter. 96.60% of the stock is owned by hedge funds and other institutional investors.

Several research firms have weighed in on LOXO. JMP Securities dropped their price target on Loxo Oncology from $221.00 to $215.00 and set a “buy” rating on the stock in a research note on Tuesday, November 13th. William Blair reiterated a “buy” rating on shares of Loxo Oncology in a research note on Monday, October 22nd. Cowen reiterated a “buy” rating on shares of Loxo Oncology in a research note on Monday, October 22nd. Citigroup boosted their price target on Loxo Oncology to $201.00 and gave the company a “buy” rating in a research note on Wednesday, November 28th. Finally, Piper Jaffray Companies set a $200.00 price target on Loxo Oncology and gave the company a “buy” rating in a research note on Monday, October 22nd. Seven equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $193.46.

Shares of LOXO opened at $234.43 on Friday. Loxo Oncology Inc has a 52 week low of $85.21 and a 52 week high of $234.75. The stock has a market capitalization of $7.18 billion, a PE ratio of -44.15 and a beta of 2.51.

Loxo Oncology (NASDAQ:LOXO) last issued its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.24). Loxo Oncology had a negative return on equity of 16.42% and a negative net margin of 43.49%. The company had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $38.55 million. During the same quarter in the previous year, the company earned ($2.45) EPS. As a group, research analysts expect that Loxo Oncology Inc will post -2.25 EPS for the current fiscal year.

In other Loxo Oncology news, CEO Joshua H. Bilenker sold 20,000 shares of the stock in a transaction that occurred on Tuesday, November 27th. The stock was sold at an average price of $147.26, for a total transaction of $2,945,200.00. Following the transaction, the chief executive officer now owns 164,407 shares in the company, valued at $24,210,574.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Avi Z. Naider purchased 725 shares of the stock in a transaction on Thursday, December 13th. The shares were acquired at an average price of $138.92 per share, for a total transaction of $100,717.00. Following the transaction, the director now directly owns 126,843 shares of the company’s stock, valued at approximately $17,621,029.56. The disclosure for this purchase can be found here. Insiders sold 64,000 shares of company stock worth $9,061,875 in the last 90 days. Company insiders own 17.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Chartwell Investment Partners LLC Buys 389 Shares of Loxo Oncology Inc (LOXO)” was reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://macondaily.com/2019/02/09/chartwell-investment-partners-llc-buys-389-shares-of-loxo-oncology-inc-loxo.html.

Loxo Oncology Profile

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Read More: Do You Need a Fiduciary?

Want to see what other hedge funds are holding LOXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Loxo Oncology Inc (NASDAQ:LOXO).

Institutional Ownership by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply